Temozolomide in Treating Patients With Invasive Pituitary Tumors

NCT00601289 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped funding term ended

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: temozolomide
GENETIC: DNA methylation analysis
GENETIC: microarray analysis
GENETIC: protein expression analysis
GENETIC: proteomic profiling
OTHER: laboratory biomarker analysis

Sponsor

Jonsson Comprehensive Cancer Center